With this in mind, Imatinib and Trametinib, a MEK-inhibitor, were recently combined in a mice model, showing successful killing of CML-LSCs (24), and providing the proof of principle to test this combination in humans also. The gene discussed is MAP2K7; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.